Additionally, vasomotor symptoms remain undertreated
Most of the potential prevented deaths would occur in low- and middle-income countries
Benefits seen for young adults eligible for dependent care expansion
Under most pessimistic scenario, one dose would avert fewer cervical cancer cases with difference of 3 percent over 100 years
Adjusted vaccine efficacy was 36.5 percent against the predominant subtype A(H3N2) and 37.1 percent against A(H1N1)pdm09
Clinically meaningful efficacy outcomes observed at one year maintained to two years of treatment
Referral lower for patients with mental health admissions or mental health diagnoses and with increasing age
Favorable safety profile seen for relapsed/refractory large B-cell lymphoma patients monitored as outpatients or inpatients
Inferior overall survival seen in Latine adults compared with Black patients in a multivariable analysis
Symptoms and activity improved in patients with chronic obstructive pulmonary disease and type 2 inflammation
Potential disparities in uptake seen by socioeconomic status and locality among privately insured adults
Better remission and response seen with bright light therapy before four weeks and after four weeks
Fear also tied to worse mental and physical health
Cumulative incidence of full cognitive recovery higher with postoperative SRS versus WBRT and for SRS alone versus SR + WBRT
Regardless of one or two doses, mpox antibodies wane by six to 12 months